Screener
Haemonetics HAE EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Haemonetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:09 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000313143-26-000120
FAQ
- What is Haemonetics's EPS (diluted)?
- Haemonetics (HAE) reported EPS (diluted) of $0.72 in Q2 2026.
- How has Haemonetics's EPS (diluted) changed year-over-year?
- Haemonetics's EPS (diluted) increased by 2.9% year-over-year, from $0.70 to $0.72.
- What is the long-term trend for Haemonetics's EPS (diluted)?
- Over 3 years (2022 to 2025), Haemonetics's EPS (diluted) has grown at a 57.9% compound annual growth rate (CAGR), from $0.84 to $3.31.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Haemonetics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude